Search
Albendazole
go.drugbank.com/drugs/DB00518ApprovedInvestigationalVet approvedA benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38)
Difenoxin
go.drugbank.com/drugs/DB01501ApprovedIllicitIt works mostly in the periphery and activates opioid receptors in the intestine rather than the central nervous system (CNS). [3] Difenoxin is also closely related to loperamide, but unlike loperamide … It is approved by the FDA to treat acute and chronic diarrhea.
Larotrectinib
go.drugbank.com/drugs/DB14723ApprovedInvestigational[L49821] Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. … It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805]
Lecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[L44537] Lecanemab works to reduce Aβ plaques and prevent Aβ deposition in the brain [A253947,A253952] with high selectivity to Aβ protofibrils. … [A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023.
Dihydrotachysterol
go.drugbank.com/drugs/DB01070ApprovedWithdrawnA vitamin D that can be regarded as a reduction product of vitamin D2.
Potassium hydroxide
go.drugbank.com/drugs/DB11153Approved[L1946,L1951] This ingredient has been considered as generally safe as a direct human food ingredient by the FDA, based upon the observance of several good manufacturing practice conditions of use.
Tocofersolan
go.drugbank.com/drugs/DB11635ApprovedIt was approved by the European Medicines Agency (EMA) in June 2009 under the market name Vedrop. … Cholestasis is the reduction or stoppage of bile flow, either to impaired secretion by _hepatocytes_ (liver cells) or obstruction [L2374], [L2375].
Tisagenlecleucel
go.drugbank.com/drugs/DB13881ApprovedInvestigationalIt was granted approval by FDA in August 2017 under the market name Kymriah.
Neostigmine
go.drugbank.com/drugs/DB01400ApprovedInvestigationalVet approvedA cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.